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galactosemia presenting as citrin deﬁciency: ReplyTo the Editor:
We thank Drs. Mc Kiernan and Baumann for their
comment concerning our case report of neonatal galas-
tosemia presenting as citrin deﬁciency. We agree that a
galactose free diet must be prescribed in case of neonatal
liver failure until the diagnosis of classical galactosemia
has been ruled out. Our case is a good illustration of this
recommendation. If we had done it, the diagnosis of
GALT deﬁciency would have been established sooner.
However, the aim of our paper was not to discuss the
relevance of the galactose free diet in case of neonatal li-
ver failure. In fact, the metabolic screening of our pa-
tient had been performed in a local hospital before
this child was admitted to our intensive care unit. The
aminoacid proﬁle was very similar to the proﬁle ob-
served in citrin deﬁciency and had never been described
previously in a case of GALT deﬁciency. This diagnosishypothesis led us to administer citrate and allowed to
demonstrate that cataplerosis may be involved in the
pathophysiology of GALT deﬁciency.
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Open access under CC BY-NC-ND license.What is the optimum dose of adefovir in the
treatment of chronic hepatitis B infection?To the Editor:
The phosphonate nucleotide analogue adefovir
(ADV), available as its prodrug adefovir dipivoxil, was
initially introduced for the treatment of human immu-
nodeﬁciency virus infection (dose 60–120 mg), but later
gained the attention of the hepatology community for
its role in the treatment of naı¨ve chronic hepatitis B pa-
tients, and later on lamivudine (LVD) resistant chronic
hepatitis B, albeit at a much lower dose. Till today, a
shadow of doubt remains on the truly optimum dose
of adefovir in the treatment of chronic hepatitis B
infection.
An early phase I/II study [1] had established the rapid
eﬃcacy of ADV (dose 125 mg) in inhibiting viral activity
as well as decreasing liver transaminases. However, the
short duration of treatment (4 weeks) adopted in this
study failed to ascertain the renal toxicity that the drug
has notoriously become famous for, which has been
shown to come into eﬀect after 20 weeks of use. Follow-
ing the open-label pilot study by Benhamou et al. [2],
10 mg became the universally accepted treatment dose
for chronic hepatitis B infection. This was later consoli-
dated after the results of analysis on the renal safety of
ADV 10 mg and 30 mg daily for the treatment of pa-tients with chronic hepatitis B from two major studies
were published [3], where it was established that the inci-
dence of ADV nephrotoxicity was indeed dose-related
particularly for all doses P30 mg daily, while there
was no evidence of this toxicity at the currently ap-
proved dose.
However, a more recent publication [4] echoed the
ever resonant voices of many authors who feel that this
dose led to a ‘‘suboptimal” and sometimes even disap-
pointing viral response. In this report, Hezode et al.
concluded that suboptimal responses to 10 mg daily
were due to ‘‘underdosing”, and that increasing the
dose to 20 mg daily was ‘‘beneﬁcial and safe in patients
with LVD-resistant hepatitis B”, especially when ala-
nine aminotransferase levels are elevated and/or liver
disease is severe or rapidly progressive while on
10 mg daily.
Our experience with ADV as a monotherapy for
chronic hepatitis B, at a standard dose of 10 mg, has
been short of disappointing. In a particular case of a
39-year-old male patient with persistent HbeAg positiv-
ity, no sustainable biochemical or viral response was
achieved despite treatment with several agents over a
10 year follow-up period in our clinic (Fig. 1).
Pretreatment Adefovir 10mg/day
Interferon-α 10 MU 3 
times/week
Lamivudine 100mg/day
Adefovir 20mg/day
Lamivudine 100mg/day
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Fig. 1. Treatment summary, ALT levels and HBV viral count of a 39-year-old patient with HBeAg positive chronic hepatitis B. [This ﬁgure appears in
colour on the web.]
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press, the dose was increased to 20 mg daily in June
2007, resulting in a logarithmic decrease in viral count
as well as a biochemical response, with no detrimental
eﬀects on renal function.
An excellent review by Sheperd et al. [5] evaluated the
clinical eﬃcacy and cost-eﬀectiveness of ADV treatment
for chronic hepatitis B, with monotherapy response rates
reported at between 21 and 51%. Response rates are even
lower in LVD resistant cases, with a reported ADV resis-
tance of 25% after 24 months of treatment [6]. In light of
these ﬁndings, we believe that a 10 mg daily dose of ADV
is indeed insuﬃcient in satisfactorily controlling chronic
hepatitis B infection, especially in the setting of LVD
resistance. If it is to be recommended at all, we advocate
that it should be used at an initial dose of 20 mg, albeit
with careful and close monitoring of renal functions.
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